Yong'an Pharmaceutical: First three quarters revenue 949 million yuan, net profit up 348.81% year-on-year.

Yongan Pharmaceutical announced that in the third quarter of 2026, it achieved operating revenue of 385 million yuan, a year-on-year increase of 83.53%; net profit attributable to the parent company was 71.0212 million yuan, a year-on-year increase of 446.29%. From the beginning of the year to the end of the reporting period, it achieved operating revenue of 949 million yuan, a year-on-year increase of 64.38%; net profit attributable to the parent company was 114 million yuan, a year-on-year increase of 348.81%. The performance growth was mainly due to the increase in sales volume and prices of its main product taurine and the increase in health product revenue. In addition, some directors and senior executives of the company plan to reduce their holdings by a total of no more than 452,900 shares, accounting for 0.1537% of the total share capital. As of the disclosure date of the report, the reduction had not yet been implemented.